title: Predictive value of endostatin in chronic heart failure patients with poor kidney function.
abstract: OBJECTIVE
  Increased circulating endostatin levels have been demonstrated in progressive cardiovascular (CV) and renal disorders. We investigated the predictive value of endostatin in patients with chronic heart failure (HF) and the association between endostatin and renal function.
  
  
  METHODS
  The interaction between serum endostatin, estimated glomerular filtration rate (eGFR) and predefined endpoints, including the primary endpoint (CV death, nonfatal myocardial infarction, nonfatal stroke; n = 397), all-cause mortality (n = 410), CV death (n = 335) or the coronary endpoint (n = 317), was evaluated in 1,390 patients >60 years of age with ischemic systolic HF in the Controlled Rosuvastatin Multinational Trial in HF (CORONA) population, who were randomly assigned to 10 mg rosuvastatin or placebo.
  
  
  RESULTS
  In the population as a whole, endostatin added no predictive information after full multivariable adjustment including eGFR and N-terminal pro-brain natriuretic peptide. Serum endostatin was strongly correlated with eGFR (r = 0.59, p < 0.001). After full multivariable adjustment, an association between high serum endostatin and increased risk of all-cause mortality and decreased risk of the primary and coronary endpoints was seen in HF patients with impaired and preserved renal function, respectively.
  
  
  CONCLUSIONS
  Endostatin added no predictive information regarding the adverse outcome in patients with chronic systolic HF of ischemic etiology. An increased risk of all-cause mortality was seen in patients with decreased renal function.
authors.affiliation: Research Institute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway.
authors.forename: Thor
authors.initials: T
authors.lastname: Ueland
authors.forename: Pål
authors.initials: P
authors.lastname: Aukrust
authors.forename: Ståle H
authors.initials: SH
authors.lastname: Nymo
authors.forename: John
authors.initials: J
authors.lastname: Kjekshus
authors.forename: John J V
authors.initials: JJ
authors.lastname: McMurray
authors.forename: John
authors.initials: J
authors.lastname: Wikstrand
authors.forename: Ursula-Henrike
authors.initials: UH
authors.lastname: Wienhues-Thelen
authors.forename: Dirk
authors.initials: D
authors.lastname: Block
authors.forename: Christian
authors.initials: C
authors.lastname: Zaugg
authors.forename: Lars
authors.initials: L
authors.lastname: Gullestad
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002097:C-Reactive Protein / Q000378:metabolism; D043169:Endostatins / Q000097:blood*; D005260:Female; D005464:Fluorobenzenes / Q000627:therapeutic use; D005919:Glomerular Filtration Rate / Q000502:physiology; D054143:Heart Failure, Systolic / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D007124:Immunoenzyme Techniques; D007674:Kidney Diseases / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D008297:Male; D008875:Middle Aged; D020097:Natriuretic Peptide, Brain / Q000097:blood; D011743:Pyrimidines / Q000627:therapeutic use; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D043169:Endostatins; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D020097:Natriuretic Peptide, Brain; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein